Clinical Trial Update: A Study of GPC3 Redirected Autologous T Cells for Advanced HCC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical study of GPC3-targeted autologous CAR-T cells for advanced hepatocellular carcinoma is underway. The snippet provides sponsors and phase but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• GPC3-CAR-T cells (glypican-3-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Shanghai GeneChem Co., Ltd. | Conditions: Carcinoma, Hepatocellular | Phase 1, Phase 2 | Status: UNKNOWN